title: Novel glutamatergic drugs for the treatment of mood disorders.
abstract: Mood disorders are common and debilitating, resulting in a significant public health burden. Current treatments are only partly effective and patients who have failed to respond to trials of existing antidepressant agents (eg, those who suffer from treatment-resistant depression [TRD]) require innovative therapeutics with novel mechanisms of action. Although neuroscience research has elucidated important aspects of the basic mechanisms of antidepressant action, most antidepressant drugs target monoaminergic mechanisms identified decades ago. Glutamate, the major excitatory neurotransmitter in the central nervous system, and glutamatergic dysfunction has been implicated in mood disorders. These data provide a rationale for the pursuit of glutamatergic agents as novel therapeutic agents. Here, we review preclinical and clinical investigations of glutamatergic agents in mood disorders with a focus on depression. We begin with discussion of evidence for the rapid antidepressant effects of ketamine, followed by studies of the antidepressant efficacy of the currently marketed drugs riluzole and lamotrigine. Promising novel agents currently in development, including N-methyl-D-aspartate (NMDA) receptor modulators, 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl) propanoic acid (AMPA) receptor modulators, and drugs with activity at the metabotropic glutamate (mGlu) receptors are then reviewed. Taken together, both preclinical and clinical evidence exists to support the pursuit of small molecule modulators of the glutamate system as novel therapeutic agents in mood disorders. It is hoped that by targeting neural systems outside of the monoamine system, more effective and perhaps faster acting therapeutics can be developed for patients suffering from these disabling disorders.
authors: Mood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
authors: Kyle Ab
authors: KA
authors: Lapidus
authors: Laili
authors: L
authors: Soleimani
authors: James W
authors: JW
authors: Murrough
keywords: AMPA; NMDA; glutamate; ketamine; major depressive disorder; mood disorders
references: Bipolar Disord. 2012 Feb;14(1):54-63
references: 22329472
references: Science. 2010 Jul 30;329(5991):502-4
references: 20671165
references: Psychol Med. 2012 Jun;42(6):1131-49
references: 22008447
references: Neuropsychopharmacology. 2010 Feb;35(3):834-46
references: 19956089
references: Mol Psychiatry. 2002;7 Suppl 1:S71-80
references: 11986998
references: Neuropharmacology. 2004 Mar;46(4):457-67
references: 14975669
references: Eur J Pharmacol. 2008 Sep 11;592(1-3):96-102
references: 18634781
references: Drugs R D. 2012 Sep 1;12(3):127-39
references: 22852579
references: Biol Psychiatry. 2008 Feb 15;63(4):349-52
references: 17643398
references: Biol Psychiatry. 2003 Apr 15;53(8):707-42
references: 12706957
references: Brain Res. 2005 Apr 25;1042(1):92-8
references: 15823257
references: Arch Gen Psychiatry. 2003 Apr;60(4):392-400
references: 12695317
references: J Psychopharmacol. 2012 Dec;26(12):1525-39
references: 22954616
references: J Clin Psychopharmacol. 2012 Dec;32(6):787-96
references: 23131884
references: J Clin Psychiatry. 2011 Oct;72(10):1405-12
references: 21367355
references: Biol Psychiatry. 2013 Aug 15;74(4):250-6
references: 22840761
references: J Clin Psychiatry. 2003 Apr;64(4):403-7
references: 12716240
references: Med Hypotheses. 2011 May;76(5):717-9
references: 21367535
references: Prim Care Companion J Clin Psychiatry. 2008;10(3):187-90
references: 18615166
references: Eur J Pharmacol. 1990 Aug 21;185(1):1-10
references: 2171955
references: Arch Gen Psychiatry. 2006 Aug;63(8):856-64
references: 16894061
references: Neuropharmacology. 2001 Jun;40(8):1028-33
references: 11406194
references: Arch Gen Psychiatry. 2010 Aug;67(8):793-802
references: 20679587
references: J Clin Psychopharmacol. 2000 Dec;20(6):607-14
references: 11106131
references: Int Clin Psychopharmacol. 2007 May;22(3):179-82
references: 17414745
references: Am J Psychiatry. 2006 Jan;163(1):153-5
references: 16390905
references: Cell Mol Neurobiol. 2003 Jun;23(3):419-30
references: 12825836
references: Behav Brain Res. 2011 Jan 1;216(1):46-52
references: 20620171
references: Biol Psychiatry. 2013 Aug 15;74(4):257-64
references: 23206319
references: J Neurogenet. 2011 Dec;25(4):152-66
references: 22091727
references: Neuroscience. 2011 May 19;182:88-97
references: 21440043
references: J Pharmacol Exp Ther. 1994 Apr;269(1):95-102
references: 8169857
references: J Clin Psychiatry. 2011 Mar;72(3):414-5
references: 21450159
references: Neuropsychobiology. 1998 Oct;38(3):131-8
references: 9778600
references: Expert Opin Drug Metab Toxicol. 2008 Sep;4(9):1223-34
references: 18721116
references: Brain Res Rev. 2009 Oct;61(2):105-23
references: 19481572
references: Nature. 2011 Jul 06;475(7354):27-30
references: 21734685
references: Neuropsychopharmacology. 2007 Sep;32(9):1888-902
references: 17299517
references: Neuropharmacology. 2009 Sep;57(3):227-34
references: 19539634
references: Mol Psychiatry. 2010 May;15(5):501-11
references: 18825147
references: J Pharmacol Exp Ther. 2006 Oct;319(1):254-9
references: 16803860
references: Science. 1991 Dec 6;254(5037):1515-8
references: 1835799
references: Psychiatr Clin North Am. 1996 Jun;19(2):179-200
references: 8827185
references: Pharmacol Biochem Behav. 2001 Oct-Nov;70(2-3):187-92
references: 11701187
references: J Psychiatry Neurosci. 2005 Jul;30(4):275-82
references: 16049571
references: Neuroscience. 1993 Oct;56(3):539-55
references: 7902967
references: Neuropharmacology. 2013 Mar;66:202-14
references: 22551786
references: Drugs. 2012 Jul 9;72(10):1313-33
references: 22731961
references: J Neurosci. 2001 Aug 15;21(16):5925-34
references: 11487615
references: Arch Gen Psychiatry. 2003 Mar;60(3):261-9
references: 12622659
references: Arch Gen Psychiatry. 2007 Sep;64(9):1099-100; author reply 1100-1
references: 17768278
references: Pol J Pharmacol. 2000 Sep-Oct;52(5):337-44
references: 11334225
references: Neuropharmacology. 2000 Sep;39(12):2278-87
references: 10974311
references: Eur Neuropsychopharmacol. 2006 Aug;16(6):451-8
references: 16503122
references: Neuropharmacology. 2007 Jul;53(1):27-36
references: 17543354
references: Neuropsychopharmacology. 2013 Apr;38(5):729-42
references: 23303054
references: Stroke. 1997 Nov;28(11):2230-6; discussion 2237
references: 9368570
references: Am J Psychiatry. 2006 Feb;163(2):210-6
references: 16449473
references: Biol Psychiatry. 2000 Feb 15;47(4):305-13
references: 10686265
references: Addiction. 2009 Jan;104(1):77-87
references: 19133891
references: Psychopharmacology (Berl). 2012 Feb;219(3):805-14
references: 21779782
references: Neuropharmacology. 2004 Feb;46(2):151-9
references: 14680755
references: J Clin Psychopharmacol. 2012 Aug;32(4):551-7
references: 22722512
references: Curr Pharm Des. 2013;19(10):1898-922
references: 23173582
references: Amino Acids. 2007 Feb;32(2):169-72
references: 16868652
references: Neuropharmacology. 2002 Jul;43(1):1-10
references: 12213254
references: Science. 2010 Aug 20;329(5994):959-64
references: 20724638
references: Biol Psychiatry. 2013 Jun 15;73(12):1180-8
references: 23273725
references: JAMA. 2004 Dec 15;292(23):2901-8
references: 15598922
references: Neuropharmacology. 2010 Dec;59(7-8):627-34
references: 20713068
references: Neuropsychopharmacology. 2009 Aug;34(9):2057-71
references: 19295507
references: Arch Gen Psychiatry. 2004 Jul;61(7):705-13
references: 15237082
references: Biol Psychiatry. 2010 Jan 15;67(2):139-45
references: 19897179
references: Nature. 1999 Jan 7;397(6714):72-6
references: 9892356
references: Int J Neuropsychopharmacol. 2010 Feb;13(1):71-82
references: 19288975
references: Biol Psychiatry. 2007 Dec 1;62(11):1310-6
references: 17574216
references: Br J Pharmacol. 2001 Apr;132(7):1423-30
references: 11264235
references: Science. 1989 Jun 16;244(4910):1360-2
references: 2660263
references: N Engl J Med. 1994 Mar 3;330(9):585-91
references: 8302340
references: Pol J Pharmacol. 2002 Nov-Dec;54(6):707-10
references: 12866729
references: Curr Psychiatry Rep. 2012 Dec;14(6):643-9
references: 22996298
references: Science. 2012 Oct 5;338(6103):68-72
references: 23042884
references: Eur J Pharmacol. 1998 Sep 25;358(1):19-24
references: 9809864
references: Eur Neuropsychopharmacol. 2007 Feb;17(3):172-9
references: 16630709
references: Am J Psychiatry. 2006 Jan;163(1):28-40
references: 16390886
references: Prog Neuropsychopharmacol Biol Psychiatry. 2012 Oct 1;39(1):102-6
references: 22651960
references: Neuropharmacology. 2005 Dec;49(7):1077-87
references: 16051282
references: Psychopharmacology (Berl). 2001 Nov;158(2):205-12
references: 11702095
references: Ann Emerg Med. 1990 Sep;19(9):1033-46
references: 2203290
references: Am J Psychiatry. 2004 Jan;161(1):171-4
references: 14702270
references: Biol Psychiatry. 2005 Feb 15;57(4):430-2
references: 15705360
references: Int J Neuropsychopharmacol. 2011 Sep;14(8):1091-8
references: 20846461
references: J Pharmacol Exp Ther. 2003 Sep;306(3):1068-76
references: 12805481
references: Neuropsychopharmacology. 2012 May;37(6):1526-33
references: 22298121
references: Biol Psychiatry. 2000 Feb 15;47(4):351-4
references: 10686270
references: Neuropharmacology. 2013 Mar;66:225-35
references: 22634361
references: Am J Psychiatry. 1959 May;115(11):1025-6
references: 13637281
references: Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10;40:12-7
references: 22960607
references: J Clin Psychiatry. 2002 Apr;63(4):337-44
references: 12000208
references: J Affect Disord. 2012 May;138(3):295-300
references: 22326841
references: J Biomol Screen. 2010 Jul;15(6):653-62
references: 20508255
references: Psychopharmacology (Berl). 2007 Nov;194(4):555-62
references: 17622518
references: Pharmacol Rep. 2010 Nov-Dec;62(6):1186-90
references: 21273676
references: J Affect Disord. 2006 Jul;93(1-3):239-43
references: 16677714
references: Am J Psychiatry. 2006 Nov;163(11):1905-17
references: 17074942
references: Biol Psychiatry. 2002 Feb 1;51(3):253-60
references: 11839368
references: Pharmacol Rep. 2008 Nov-Dec;60(6):865-71
references: 19211978
references: J Clin Psychiatry. 2000 Nov;61(11):841-50
references: 11105737
references: Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):380-6
references: 17933448
references: Biol Psychiatry. 2012 Jun 1;71(11):939-46
references: 22297150
references: Nat Med. 2010 Dec;16(12):1384-5
references: 21135850
references: Eur J Pharmacol. 1998 Oct 16;359(1):27-32
references: 9831289
references: J Clin Psychopharmacol. 2008 Dec;28(6):631-7
references: 19011431
references: Biol Psychiatry. 2007 Mar 15;61(6):822-5
references: 17141740
references: Eur J Pharmacol. 2002 Apr 5;440(1):27-35
references: 11959085
references: Pharmacol Biochem Behav. 2005 Aug;81(4):901-6
references: 16040106
references: Am J Psychiatry. 2010 Nov;167(11):1305-20
references: 20843874
references: Biol Psychiatry. 2011 Apr 15;69(8):754-61
references: 21292242
references: Int J Neuropsychopharmacol. 2013 Apr;16(3):501-6
references: 23174090
references: J Clin Psychiatry. 2003 Sep;64(9):1013-24
references: 14628976
references: Depress Anxiety. 2006;23(8):485-8
references: 16845646
references: J Clin Psychiatry. 2004 Mar;65(3):432-41
references: 15096085
references: Psychopharmacology (Berl). 2006 Jul;186(4):587-93
references: 16612616